Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid

FASEB Journal

Volumn 30, Issue 11, 2016, Pages 3714-3725

  Markworth, James F ^a   Kaur, Gunveen ^b   Miller, Eliza G ^b   Larsen, Amy E ^c   Sinclair, Andrew J ^d   Maddipati, Krishna Rao ^e,f   Cameron Smith, David ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b DEAKIN UNIVERSITY   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e Department of Pathology   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

Author keywords

Eicosanoids; Fish Oil; Inflammation; Lipidomics; Omega 3 Fatty Acids

Indexed keywords

ARACHIDONIC ACID; DIHOMO GAMMA LINOLENIC ACID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; FATTY ACID; UNSATURATED FATTY ACID;

ADULT; ARTICLE; AUSTRALIAN; BIOSYNTHESIS; CROSSOVER PROCEDURE; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; ISOMER; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPIDOMICS; LIQUID CHROMATOGRAPHY; MACROPHAGE; METABOLITE; NEUTROPHIL; PLASMA; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; DIET; DIETARY SUPPLEMENT; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADULT; CROSS-OVER STUDIES; DIET; DIETARY SUPPLEMENTS; EICOSAPENTAENOIC ACID; FATTY ACIDS; FATTY ACIDS, OMEGA-3; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; LIPID METABOLISM; YOUNG ADULT;

EID: 84995640031     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.201600360R     Document Type: Article

References (74)

1. Flachs, P., Rossmeisl, M and Kopecky, J. 2014. The effect of n-3 fatty acids on glucose homeostasis and insulin sensitivity. Physiol. Res. 63 (Suppl 1):S93-S118.
2. Gerber, P. A., Gouni-Berthold, I., and Berneis, K. (2013) Omega-3 fatty acids: role inmetabolismandcardiovascular disease.Curr.Pharm. Des. 19, 3074-3093
3. Janssen, C. I. F., and Kiliaan, A. J. (2014) Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: The influence of LCPUFA on neural development, aging, and neurodegeneration. Prog. Lipid Res. 53, 1-17
4. Lorente-Cebrían, S., Costa, A. G. V., Navas-Carretero, S., Zabala, M., Martinez, J.A., andMoreno-Aliaga, M. J. (2013)Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: A review of the evidence. J. Physiol. Biochem. 69, 633-651
5. Stables, M. J., and Gilroy, D. W. (2011)Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 50, 35-51
6. Schmitz, G., and Ecker, J. (2008) The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47, 147-155
7. Bannenberg, G. L., Chiang, N., Ariel, A., Arita, M., Tjonahen, E., Gotlinger, K. H., Hong, S., and Serhan, C. N. (2005) Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 174, 4345-4355
8. Serhan, C. N. (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101
9. Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N., and Bazan, N. G. (2004) Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells fromoxidative stress. Proc. Natl. Acad. Sci. USA 101, 8491-8496
10. Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., and Spite, M. (2009) Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J. Exp. Med. 206, 15-23
11. Lu, Y., Tian, H., and Hong, S. (2010) Novel 14, 21-dihydroxydocosahexaenoic acids: structures, formation pathways, and enhancement of wound healing. J. Lipid Res. 51, 923-932
12. Hong, S., Gronert, K., Devchand, P.R., Moussignac, R.-L., andSerhan, C. N. (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid inmurine brain, human blood, and glial cells: Autacoids in anti-inflammation. J. Biol. Chem. 278, 14677-14687
13. Marcheselli, V. L., Hong, S., Lukiw, W. J., Tian, X. H., Gronert, K., Musto, A., Hardy, M., Gimenez, J.M., Chiang, N., Serhan, C. N., and Bazan, N. G. (2003) Novel docosanoids inhibit brain ischemiareperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43807-43817
14. Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., and Moussignac, R.-L. (2002) Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037
15. Serhan, C. N., Gotlinger, K., Hong, S., and Arita, M. (2004) Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-Triggered endogenous epimers: An overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat. 73, 155-172
16. Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., and Gronert, K. (2000) Novel functional sets of lipid-derived mediators with antiinflammatory actions generated fromomega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204
17. Arita, M., Clish, C. B., and Serhan, C. N. (2005) The contributions of aspirin and microbial oxygenase to the biosynthesis of antiinflammatory resolvins: novel oxygenase products from omega-3 polyunsaturated fatty acids. Biochem. Biophys. Res. Commun. 338, 149-157
18. Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., andSerhan, C. N. (2011) Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569-581
19. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N. A., and Serhan, C. N. (2005) Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J. Exp. Med. 201, 713-722
20. Tjonahen, E., Oh, S. F., Siegelman, J., Elangovan, S., Percarpio, K. B., Hong, S., Arita, M., andSerhan, C.N. (2006) Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. Chem. Biol. 13, 1193-1202
21. Oh, S. F., Dona, M., Fredman, G. , Krishnamoorthy, S., Irimia, D., and Serhan, C.N. 2012. Resolvin E2 formation and impact in inflammation resolution. J. Immunol. 188, 4527-4534
22. Isobe, Y., Arita, M., Iwamoto, R., Urabe, D., Todoroki, H., Masuda, K., Inoue, M., and Arai, H. (2013) Stereochemical assignment and antiinflammatory properties of the omega-3 lipid mediator resolvin E3. J. Biochem. 153, 355-360
23. Isobe, Y., Arita, M., Matsueda, S., Iwamoto, R., Fujihara, T., Nakanishi, H., Taguchi, R., Masuda, K., Sasaki, K., Urabe, D., Inoue, M., andArai, H. (2012) Identification and structure determination of novel antiinflammatory mediator resolvin E3, 17, 18-dihydroxyeicosapentaenoic acid. J. Biol. Chem. 287, 10525-10534
24. Urabe, D., Todoroki, H., Masuda, K., and Inoue, M. (2012) Total syntheses of four possible stereoisomers of resolvin E3. Tetrahedron 68, 3210-3219
25. Westphal, C., Konkel, A., and Schunck, W.-H. (2011) CYPeicosanoids-A new link between omega-3 fatty acids and cardiac disease? Prostaglandins Other Lipid Mediat. 96, 99-108
26. Yanai, R., Mulki, L., Hasegawa, E., Takeuchi, K., Sweigard, H., Suzuki, J., Gaissert, P., Vavvas, D. G., Sonoda, K.-H., Rothe, M., Schunck, W.-H., Miller, J. W., and Connor, K. M. (2014) Cytochrome P450-generated metabolites derived from v-3 fatty acids attenuate neovascularization. Proc. Natl. Acad. Sci. USA 111, 9603-9608
27. Arnold, C., Markovic, M., Blossey, K., Wallukat, G., Fischer, R., Dechend, R., Konkel, A., von Schacky, C., Luft, F. C., Muller, D. N., Rothe, M., andSchunck, W.-H. (2010)Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of omega-3 fatty acids. J. Biol. Chem. 285, 32720-32733
28. Morisseau, C., andHammock, B. D. (2013)Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu. Rev. Pharmacol. Toxicol. 53, 37-58
29. Kaur, G., Cameron-Smith, D., Garg, M., and Sinclair, A. J. (2011) Docosapentaenoic acid (22:5n-3): A review of its biological effects. Prog. Lipid Res. 50, 28-34
30. EFSA Panel on Dietetic Products, Nutrition and Allergies. (2012) Scientific opinion on the tolerable upper intake level of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA). EFSA J. 10, 2815-2865
31. U.S. Department of Agriculture Agricultural Research Service and Nutrient Data Laboratory. (2015) USDANational Nutrient Database for Standard Reference, Release 28. Version Current: September 2015, slightly revised May 2016. U.S. Department of Agriculture, Washington, DC. Accessed May 17, 2016 at: http://www.ars.usda. gov/nea/bhnrc/ndl
32. Miller, E., Kaur, G., Larsen, A., Loh, S. P., Linderborg, K., Weisinger, H. S., Turchini, G.M., Cameron-Smith, D., and Sinclair, A. J. (2013) A short-Termn-3DPAsupplementationstudy inhumans.Eur. J. Nutr. 52, 895-904
33. Kaur, G., Begg, D. P., Barr, D., Garg, M., Cameron-Smith, D., and Sinclair, A. J. (2010) Short-Term docosapentaenoic acid (22:5 n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats. Br. J. Nutr. 103, 32-37
34. Dalli, J., Colas, R. A., and Serhan, C. N. (2013) Novel n-3 immunoresolvents: structures and actions. Sci. Rep. 3, 1940
35. Sullivan, B. L., Brown, J., Williams, P. G., and Meyer, B. J. (2008) Dietary validation of a new Australian food-frequency questionnaire that estimates long-chain n-3 polyunsaturated fatty acids. Br. J. Nutr. 99, 660-666
36. Sullivan, B., Williams, P., and Meyer, B. (2006) Biomarker validation of a long-chain omega-3 polyunsaturated fatty acid food frequency questionnaire. Lipids 41, 845-850
37. Swierk, M., Williams, P. G., Wilcox, J., Russell, K. G., and Meyer, B. J. (2011) Validation of an Australian electronic food frequency questionnaire to measure polyunsaturated fatty acid intake. Nutrition 27, 641-646
38. Maddipati, K. R., and Zhou, S.-L. (2011) Stability and analysis of eicosanoids and docosanoids in tissue culture media. Prostaglandins Other Lipid Mediat. 94, 59-72
39. Markworth, J. F., Vella, L., Lingard, B. S., Tull, D. L., Rupasinghe, T. W., Sinclair, A. J., Maddipati, K. R., and Cameron-Smith, D. (2013) Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R1281-R1296
40. Akiba, S., Murata, T., Kitatani, K., and Sato, T. (2000) Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation. Biol. Pharm. Bull. 23, 1293-1297
41. Phang, M., Garg, M. L., and Sinclair, A. J. (2009) Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specific-Redefining platelet response to fish oils. Prostaglandins Leukot. Essent. Fatty Acids 81, 35-40
42. Kanayasu-Toyoda, T., Morita, I., and Murota, S. (1996) Docosapentaenoic acid (22:5, n-3), an elongation metabolite of eicosapentaenoic acid (20:5, n-3), is a potent stimulator of endothelial cellmigration on pretreatment in vitro. Prostaglandins Leukot. Essent. Fatty Acids 54, 319-325
43. Tsuji, M., Murota, S. I., and Morita, I. (2003) Docosapentaenoic acid (22:5, n-3) suppressed tube-forming activity in endothelial cells induced by vascular endothelial growth factor. Prostaglandins Leukot. Essent. Fatty Acids 68, 337-342
44. Morin, C., Rousseau, E., andFortin, S. (2013)Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins Leukot. Essent. Fatty Acids 89, 203-213
45. Kaur, G., Sinclair, A. J., Cameron-Smith, D., Barr, D. P., Molero-Navajas, J. C., andKonstantopoulos, N. (2011) Docosapentaenoic acid(22:5n-3) down-regulates the expression of genes involved in fat synthesis in liver cells. Prostaglandins Leukot. Essent. Fatty Acids 85, 155-161
46. Holub, B. J., Swidinsky, P., and Park, E. (2011)Oral docosapentaenoic acid (22:5n-3) is differentially incorporated into phospholipid pools and differentially metabolized to eicosapentaenoic acid in tissues from young rats. Lipids 46, 399-407
47. Chen, J., Jiang, Y., Liang, Y., Tian, X., Peng, C., Ma, K. Y., Liu, J., Huang, Y., and Chen, Z.-Y. (2012) DPA n-3, DPA n-6 and DHA improve lipoprotein profiles and aortic function in hamsters fed a high cholesterol diet. Atherosclerosis 221, 397-404
48. Gotoh, N., Nagao, K., Onoda, S., Shirouchi, B., Furuya, K., Nagai, T., Mizobe, H., Ichioka, K., Watanabe, H., Yanagita, T., and Wada, S. (2009) Effects of three different highly purified n-3 series highly unsaturated fatty acids on lipid metabolism in C57BL/KsJ-db/db mice. J. Agric. Food Chem. 57, 11047-11054
49. Kelly, L., Grehan, B., Chiesa, A. D., O'Mara, S. M., Downer, E., Sahyoun, G., Massey, K. A., Nicolaou, A., and Lynch, M. A. (2011) The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol. Aging 32, 2318.e1-2318. e15
50. Oda, E., Hatada, K., Katoh, K., Kodama, M., Nakamura, Y., and Aizawa, Y. (2005) A case-control pilot study on n-3 polyunsaturated fatty acid as a negative risk factor for myocardial infarction. Int. Heart J. 46, 583-591
51. Rissanen, T., Voutilainen, S., Nyyssönen, K., Lakka, T. A., and Salonen, J.T. (2000)Fish oil-derivedfatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: The Kuopio ischaemic heart disease risk factor study. Circulation 102, 2677-2679
52. Paganelli, F., Maixent, J. M., Duran, M. J., Parhizgar, R., Pieroni, G., and Sennoune, S. (2001) Altered erythrocyte n-3 fatty acids in Mediterranean patients with coronary artery disease. Int. J. Cardiol. 78, 27-32
53. Sun, Q., Ma, J., Campos, H., Rexrode, K. M., Albert, C. M., Mozaffarian, D., and Hu, F. B. (2008) Blood concentrations of individual long-chain n-3 fatty acids and risk of nonfatal myocardial infarction. Am. J. Clin. Nutr. 88, 216-223
54. Fischer, R., Konkel, A., Mehling, H., Blossey, K., Gapelyuk, A., Wessel, N., vonSchacky, C., Dechend, R.Muller, D.N., Rothe, M., Luft, F. C., Weylandt, K. and Schunck, W.-H. (2014). Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYPepoxygenase pathway. J. Lipid Res. 55, 1150-1164
55. Keenan, A. H., Pedersen, T. L., Fillaus, K., Larson, M. K., Shearer, G. C., and Newman, J.W. (2012) Basal omega-3 fatty acid status affects fatty acid and oxylipin responses to high-dose n3-HUFA in healthy volunteers. J. Lipid Res. 53, 1662-1669
56. Lundström, S. L., Yang, J., Brannan, J. D., Haeggström, J. Z., Hammock, B. D., Nair, P., O'Byrne, P., Dahĺen, S.-E., andWheelock, C. E. (2013) Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids. Mol. Nutr. Food Res. 57, 1378-1389
57. Schuchardt, J. P., Schmidt, S., Kressel, G., Willenberg, I., Hammock, B. D., Hahn, A., and Schebb, N. H. (2014) Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper-And normolipidemic men. Prostaglandins Leukot. Essent. Fatty Acids 90, 27-37
58. Shearer, G. C., Harris, W. S., Pedersen, T. L., and Newman, J. W. (2010) Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters. J. Lipid Res. 51, 2074-2081
59. Mas, E., Barden, A., Burke, V., Beilin, L. J., Watts, G. F., Huang, R. C., Puddey, I. B., Irish, A. B., and Mori, T. A. (2016) A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease. Clin. Nutr. 35, 331-336.
60. Schebb, N.H., Ostermann, A. I., Yang, J., Hammock, B. D., Hahn, A., and Schuchardt, J. P. (2014) Comparison of the effects of long-chain omega-3 fatty acid supplementation on plasma levels of free and esterified oxylipins. Prostaglandins Other Lipid Mediat. 113-115, 21-29
61. Zulyniak, M. A., Perreault, M., Gerling, C., Spriet, L. L., and Mutch, D. M. (2013) Fish oil supplementation alters circulating eicosanoid concentrations in young healthy men. Metabolism 62, 1107-1113
62. Skarke, C., Alamuddin, N., Lawson, J. A., Li, X., Ferguson, J.F., Reilly, M. P., and FitzGerald, G. A. (2015) Bioactive products formed in humans from fish oils. J. Lipid Res. 56, 1808-1820
63. Dawczynski, C., Massey, K. A., Ness, C., Kiehntopf, M., Stepanow, S., Platzer, M., Grün, M., Nicolaou, A., and Jahreis, G. (2013) Randomized placebo-controlled intervention with n-3 LC-PUFAsupplemented yoghurt: effects on circulating eicosanoids and cardiovascular risk factors. Clin. Nutr. 32, 686-696
64. Gomolka, B., Siegert, E., Blossey, K., Schunck, W.-H., Rothe, M., andWeylandt, K.H. (2011) Analysis of omega-3 and omega-6 fatty acid-derived lipid metabolite formation in human and mouse blood samples. Prostaglandins Other Lipid Mediat. 94, 81-87
65. Colas, R. A., Shinohara, M., Dalli, J., Chiang, N., and Serhan, C. N. (2014) Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307, C39-C54
66. Barden, A., Mas, E., Croft, K. D., Phillips, M., and Mori, T. A. (2014) Short-Term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation. J. Lipid Res. 55, 2401-2407
67. Mas, E., Croft, K. D., Zahra, P., Barden, A., and Mori, T. A. (2012) Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. Clin. Chem. 58, 1476-1484
68. Psychogios, N., Hau, D. D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., Sinelnikov, I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., Huang, P., Hollander, Z., Pedersen, T. L., Smith, S. R., Bamforth, F., Greiner, R., McManus, B., Newman, J. W., Goodfriend, T., and Wishart, D. S. (2011) The human serum metabolome. PLoS One 6, e16957
69. Murphy, R. C. (2015) Specialized pro-resolving mediators: do they circulate in plasma? J. Lipid Res. 56, 1641-1642
70. Schuchardt, J. P., Schneider, I., Willenberg, I., Yang, J., Hammock, B. D., Hahn, A., and Schebb, N. H. (2014) Increase of EPA-derived hydroxy, epoxy and dihydroxy fatty acid levels in human plasma after a single dose of long-chain omega-3 PUFA. Prostaglandins Other Lipid Mediat. 109-111, 23-31
71. Yamada, H., Oshiro, E., Kikuchi, S., Hakozaki, M., Takahashi, H., and Kimura, K. (2014) Hydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs. J. Lipid Res. 55, 895-904
72. Harmon, G. S., Dumlao, D. S., Ng, D. T., Barrett, K. E., Dennis, E. A., Dong, H., and Glass, C. K. (2010) Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice. Nat. Med. 16, 313-318
73. Lu, D., Han, C., and Wu, T. (2014) 15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE2/PPARg-mediated activation of p21WAF1/Cip1. Oncogene 33, 1101-1112
74. Ghasemifard, S., Turchini, G. M., and Sinclair, A. J. (2014) Omega-3 long chain fatty acid "bioavailability": A review of evidence and methodological considerations. Prog. Lipid Res. 56, 92-108